Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).

P Joy HoLay TayJuliana TeoPaula MarltonAndrew GriggTim G St PierreGreg BrownCaro-Anne BadcockRobert TraficanteOthon L GervasioDonald K Bowden

Published in: European journal of haematology (2016)

Once-daily deferasirox over 1 yr significantly increased myocardial T2* and reduced LIC. This confirms that single-agent deferasirox is effective in the management of cardiac iron, especially for patients with myocardial T2* >10 ms (Clinicaltrials.gov identifier: NCT00673608).

Keyphrases

left ventricular
mass spectrometry
iron deficiency
ms ms
physical activity
heart failure
red blood cell